Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1959 1
1963 2
1967 1
2006 3
2007 1
2008 2
2009 5
2010 5
2011 8
2012 10
2013 5
2014 5
2015 8
2016 11
2017 11
2018 11
2019 6
2020 3
2021 6
2022 5
2023 4
2024 4
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

99 results

Results by year

Filters applied: . Clear all
Page 1
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.
Westin SN, Moore K, Chon HS, Lee JY, Thomes Pepin J, Sundborg M, Shai A, de la Garza J, Nishio S, Gold MA, Wang K, McIntyre K, Tillmanns TD, Blank SV, Liu JH, McCollum M, Contreras Mejia F, Nishikawa T, Pennington K, Novak Z, De Melo AC, Sehouli J, Klasa-Mazurkiewicz D, Papadimitriou C, Gil-Martin M, Brasiuniene B, Donnelly C, Del Rosario PM, Liu X, Van Nieuwenhuysen E; DUO-E Investigators. Westin SN, et al. J Clin Oncol. 2024 Jan 20;42(3):283-299. doi: 10.1200/JCO.23.02132. Epub 2023 Oct 21. J Clin Oncol. 2024. PMID: 37864337 Free PMC article. Clinical Trial.
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
Geyer CE Jr, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, Aktan G, Armstrong AC, Arnedos M, Balmaña J, Bergh J, Bliss J, Delaloge S, Domchek SM, Eisen A, Elsafy F, Fein LE, Fielding A, Ford JM, Friedman S, Gelmon KA, Gianni L, Gnant M, Hollingsworth SJ, Im SA, Jager A, Jóhannsson ÓÞ, Lakhani SR, Janni W, Linderholm B, Liu TW, Loman N, Korde L, Loibl S, Lucas PC, Marmé F, Martinez de Dueñas E, McConnell R, Phillips KA, Piccart M, Rossi G, Schmutzler R, Senkus E, Shao Z, Sharma P, Singer CF, Španić T, Stickeler E, Toi M, Traina TA, Viale G, Zoppoli G, Park YH, Yerushalmi R, Yang H, Pang D, Jung KH, Mailliez A, Fan Z, Tennevet I, Zhang J, Nagy T, Sonke GS, Sun Q, Parton M, Colleoni MA, Schmidt M, Brufsky AM, Razaq W, Kaufman B, Cameron D, Campbell C, Tutt ANJ; OlympiA Clinical Trial Steering Committee and Investigators. Geyer CE Jr, et al. Ann Oncol. 2022 Dec;33(12):1250-1268. doi: 10.1016/j.annonc.2022.09.159. Epub 2022 Oct 10. Ann Oncol. 2022. PMID: 36228963 Free PMC article. Clinical Trial.
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, McFadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, Geyer CE Jr; OlympiA Clinical Trial Steering Committee and Investigators. Tutt ANJ, et al. N Engl J Med. 2021 Jun 24;384(25):2394-2405. doi: 10.1056/NEJMoa2105215. Epub 2021 Jun 3. N Engl J Med. 2021. PMID: 34081848 Free PMC article. Clinical Trial.
Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial.
Harbeck N, Fasching PA, Wuerstlein R, Degenhardt T, Lüftner D, Kates RE, Schumacher J, Räth P, Hoffmann O, Lorenz R, Decker T, Reinisch M, Göhler T, Staib P, Gluz O, Schinköthe T, Schmidt M; AGO-B WSG PreCycle investigators (see Appendix 1). Harbeck N, et al. Ann Oncol. 2023 Aug;34(8):660-669. doi: 10.1016/j.annonc.2023.05.003. Epub 2023 May 16. Ann Oncol. 2023. PMID: 37201751 Free article. Clinical Trial.
Lost axillary markers after neoadjuvant chemotherapy in breast cancer patients - data from the prospective international AXSANA (EUBREAST 3) cohort study (NCT04373655).
Hartmann S, Banys-Paluchowski M, Berger T, Ditsch N, Stickeler E, de Boniface J, Gentilini OD, Schroth J, Karadeniz Cakmak G, Rubio IT, Gasparri ML, Kontos M, Bonci EA, Niinikoski L, Murawa D, Kadayaprath G, Pinto D, Peintinger F, Schlichting E, Dostalek L, Nina H, Valiyeva H, Vanhoeij M, Perhavec A, Zippel D, Rebaza LP, Thongvitokomarn S, Fröhlich S, Ruf F, Rief A, Wihlfahrt K, Basali T, Thill M, Lux MP, Loibl S, Kolberg HC, Blohmer JU, Hahn M, Gurleyik MG, Porpiglia M, Gunay S, Zetterlund L, Kuehn T; AXSANA Study Group. Hartmann S, et al. Eur J Surg Oncol. 2025 Sep;51(9):110253. doi: 10.1016/j.ejso.2025.110253. Epub 2025 Jun 25. Eur J Surg Oncol. 2025. PMID: 40587927 Free article.
Axillary dissection for low-volume nodal involvement after neoadjuvant therapy in breast cancer: multicentre AXSANA cohort study.
Kühn T, Banys-Paluchowski M, Ditsch N, Stickeler E, Hauptmann M, Schroth J, Karadeniz Cakmak G, Hahn M, Thill M, Reimer T, Fröhlich S, Schmidt E, Wihlfahrt K, Berger T, Basali T, Ruf F, Rief A, Lux MP, Kolberg HC, Rubio IT, Gasparri ML, Kontos M, Bonci EA, Niinikoski L, Murawa D, Pinto D, Peintinger F, Schlichting E, Nina H, Valiyeva Qanimat H, Vanhoeij M, Rebaza LP, Aktas Sezen B, Jursik K, Kadayaprath G, Dostalek L, Kothari A, Perhavec A, Ivanov T, Zippel D, Thongvitokomarn S, Gurleyik MG, Watermann D, Porpiglia M, Lebeau A, Di Micco R, Gentilini OD, de Boniface J, Hartmann S; AXSANA Study Group. Kühn T, et al. Br J Surg. 2025 Sep 2;112(9):znaf180. doi: 10.1093/bjs/znaf180. Br J Surg. 2025. PMID: 40966675
99 results